USPTO 2015–2025 USPTO PatentsView Foreign Corporation

UCB Pharma S.a.

USPTO PatentsView assignee record - 55 granted patents across 14 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (PEPTIDES).

Compiled by PlainPatent · May 15, 2026

Explore the portfolio See the ranking

Total patents granted

CPC technology areas

16.9

Avg claims per patent

-90%

5-year grant velocity

The verdict

According to USPTO PatentsView, UCB ranks #6,200 of 50,000 tracked US assignees by granted-patent volume, with 55 patents across 14 technology areas.

#6,200
of 50,000 US assignees by volume: Top 13%
by Innovation Score (50.6/100): 16.9
avg claims per patent: -90%
grant velocity, last 5 yrs

Portfolio overview

UCB Pharma S.a. has been granted 55 US utility patents between 2015 and 2024, placing UCB Pharma S.a. at #6,200 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 14 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.9 claims per patent with primary concentration in C07K (PEPTIDES). As a Foreign Corporation, UCB Pharma S.a. is one of the more focused assignees in the PatentsView dataset. By volume, UCB sits between The North Face Apparel Corp. (55 patents, rank #6,195) and W Schonbek Llc (55 patents, rank #6,203) - the closest US assignees by grant volume. The composite Innovation Score of 50.6/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 5 grants, compared with 50 in the 2015–2019 window, a -90% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The Foreign Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. UCB Pharma S.a.'s 16.9 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 14 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

The North Face Ap…

55
The University of…

55
Theatro Labs

55
Tyco Safety Produ…

55
University Colleg…

55
University of New…

55
Vicor

55
W Schonbek

55
UCB Pharma ◀

55

What this shows UCB holds 55 patents at rank #6,199, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near UCB

By rank, the assignees closest to #6,199 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in UCB's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for UCB, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (51 here).

Namics Corporation 51 Shibaura Mechatronics Corporation 51 Gemalto Sa 51 Children's Hospital Los Angeles 51

Similar claim depth

Nearest assignees by average claims per patent (16.9 here).

Given Imaging Ltd. 16.9 avg Hideep Inc. 16.9 avg University Of Kansas 16.9 avg Integrated Device Technology, Inc. 16.9 avg

UCB's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

51 Top 13% higher than 87% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

UCB Pharma S.a. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	26	47.3%
2016	11	20.0%
2017	9	16.4%
2018	3	5.5%
2019	1	1.8%
2020	1	1.8%
2022	1	1.8%
2023	2	3.6%
2024	1	1.8%

Which technologies does UCB Pharma S.a. patent most?

C07K - PEPTIDES 41

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 24

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 20

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 17

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 8

C07D - HETEROCYCLIC COMPOUNDS 7

C12P - FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 6

Y02P - CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS 5

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 4

C12R - INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS 3

C12Y - ENZYMES 2

A01K - ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS 2

A61M - DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR 2

Y10T - TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION 1

Top 14 of 14 technology areas

Grant record at a glance

Portfolio Volume 55 grants

CPC subclasses 14

Avg. claims / grant 16.9

Velocity -90%

Historical grant data only; it does not rate legal strength or current strategy.

Where it ranks

Overall rank by patents

#6,200

of 50,000 tracked assignees

Innovation Score

50.6 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

Where does UCB Pharma S.a. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), UCB Pharma S.a. ranks #6,200 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does UCB Pharma S.a. hold?

UCB Pharma S.a. holds 55 US utility patents granted between 2015 and 2024, spanning 14 technology areas.

What is UCB Pharma S.a.'s Innovation Score?

UCB Pharma S.a. has an Innovation Score of 50.6 out of 100 (top 13% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does UCB Pharma S.a. focus on?

UCB Pharma S.a.'s top technology area is C07K (PEPTIDES) with 41 patents. Grants appear in 14 CPC subclasses total.

Is UCB Pharma S.a.'s patent grant rate increasing or decreasing?

UCB Pharma S.a.'s recent grant velocity is -90% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for UCB Pharma S.a.'s patents?

UCB Pharma S.a.'s patents average 16.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the UCB Pharma S.a. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

UCB's 55 grants land it in the top 13% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - UCB ranks #6,200 of 50,000. Top 50 holders
Most of this portfolio concentrates in C07K - see who else leads that technology area. C07K leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.